UMIN ID: C000000452
Registered date:01/08/2006
Remission Induction of Very Early Rheumatoid Arthritis with Methotrexate and Etanercept
Basic Information
| Recruitment status | Pending |
|---|---|
| Health condition(s) or Problem(s) studied | rheumatoid arthritis |
| Date of first enrollment | 2006/08/01 |
| Target sample size | 50 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | methotrexate 8mg/week methotrexate 8mg/week and etanercept(25mg x1-2/week) for 3 months methotrexate 8mg/week and etanercept(25mgx1-2/week) for 6 months |
Outcome(s)
| Primary Outcome | Inhibitiion of joint destruction as shown by Sharp score, Knee joint X-ray, and serum MMP3 levels, and remission rates evaluated by DAS28 |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | patients who are contra indicated for methotrexate or etanercept |
Related Information
| Primary Sponsor | Johoku Biological Summit |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Takeda Pharmaceutical Co. |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Shunsei Hirohata |
| Address | Japan |
| Telephone | |
| shun-tei@umin.ac.jp | |
| Affiliation | Teikyo University School of Medicine Department of Internal Medicine |
| scientific contact | |
| Name | Shunsei Hirohata |
| Address | 2-11-1 Kaga, Itabashiku, Tokyo Japan |
| Telephone | 03-3964-1211 |
| Affiliation | Teikyo University School of Medicine Department of Internal Medicine |